menu

CGRP Inhibitors Market

Schedule Call

CGRP Inhibitors Market

CGRP Inhibitors Market by Drug Class (Monoclonal Antibody and Gepants), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

GR - 979479 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: June 08, 2023

Historical Years – 2021  |  Base Year – 2022  |  Forecasted Years – 2023-2031


CGRP Inhibitors Market Scope

Report Attribute

Details

CAGR

5.4%

Base Year for Estimation

2022

Forecast Period

2023 to 2031

Historical Year

2021

Segments Covered

Drug Class, Distribution Channel, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global CGRP inhibitors market is expected to register a revenue CAGR of 5.4% from 2023 to 2031.

CGRP Inhibitors Market Fundamentals

CGRP inhibitors, also known as calcitonin gene-related peptide inhibitors, are a class of medications used to treat migraine headaches. CGRP is a neuropeptide that plays a significant role in the development of migraines. CGRP inhibitors target either the CGRP receptor or the CGRP peptide itself, blocking their actions and preventing migraine attacks. These medications are designed to reduce the frequency, severity, and duration of migraines. They are typically used as a preventive treatment rather than for acute migraine relief. There are two main types of CGRP inhibitors i.e., monoclonal antibodies and gepants. CGRP inhibitors have shown efficacy in reducing the frequency and severity of migraines in clinical trials. They provide an alternative treatment option for individuals who experience migraines that are resistant to or cannot tolerate other medications.

CGRP Inhibitors Market Dynamics

Migraine headaches are a prevalent neurological disorder, affecting a substantial portion of the global population. The burden of migraines and the associated healthcare costs have contributed to the demand for effective treatments, thus boosting the global CGRP inhibitors market. According to Migraine Statistics, migraine is one of the most common neurological disorders, which has almost 1 billion individuals globally. CGRP inhibitors are primarily used as preventive treatments for migraines, offering a proactive approach to managing the condition. This shift from acute treatment to preventive therapy aligns with the growing emphasis on disease management and improving the quality of life for migraine sufferers. Moreover, there has been a growing awareness and understanding of migraines among patients and healthcare professionals. This increased recognition has led to improved diagnosis rates and identifying individuals who could benefit from CGRP inhibitors, further driving the market.

However, CGRP inhibitors are generally expensive medications, especially monoclonal antibodies. The high cost of these drugs can limit access for some patients, particularly those without adequate insurance coverage or in regions with limited healthcare resources. Furthermore, migraine is often underdiagnosed or misdiagnosed, leading to a lack of awareness and understanding of the condition. This can result in delayed or inadequate treatment, including the use of CGRP inhibitors. Improving awareness and accurate diagnosis of migraine is crucial to increasing the adoption of CGRP inhibitors. CGRP inhibitors face competition from other established preventive and acute treatments for migraines, such as beta-blockers, antiepileptic drugs, and triptans. Moreover, physicians and patients may prefer to stick with familiar treatment options rather than adopting newer medications like CGRP inhibitors. Additionally, the high cost of treatment, limited awareness and diagnosis, and competition from established therapies are some of the restraints impeding the overall market growth. 

CGRP Inhibitors Market Ecosystem

The global CGRP inhibitors market is analyzed from three perspectives: drug class, distribution channel, and region. 

CGRP Inhibitors Market by Drug Class 

Based on the drug class, the global CGRP inhibitors market is segmented into monoclonal antibody and gepants. 

The monoclonal antibody segment accounted for a prominent revenue share of the market. The CGRP inhibitors market refers to a specific type of CGRP inhibitors that are formulated as monoclonal antibody drugs. Monoclonal antibodies are laboratory-produced molecules designed to mimic the natural antibodies produced by the immune system. Monoclonal antibodies in this segment work by binding to CGRP or its receptors, inhibiting their interaction and subsequent migraine-related effects. By blocking CGRP activity, these drugs help prevent the dilation of blood vessels and the release of inflammatory substances that contribute to migraine attacks. Several monoclonal antibody drugs have been developed and approved for the prevention of migraines, for example, eptinezumab, fremanezumab, and galcanezumab. Monoclonal antibodies used as CGRP inhibitors are typically administered through subcutaneous injections. The dosing frequency varies depending on the specific drug, but it is usually once a month or once every three months. These aspects contribute to the growth of the monoclonal antibody segment.

The gepants segment accounted for a significant revenue share of the market. Gepants are small molecule inhibitors of CGRP receptors and are distinct from the monoclonal antibodies used for preventive treatment. Gepants work by selectively blocking the CGRP receptor, preventing CGRP from binding to and activating the receptor. By inhibiting CGRP receptor signaling, gepants help alleviate the symptoms of a migraine attack, including pain, inflammation, and vasodilation. Several gepants are used in the treatment of migrane including ubrogepant, rimegepant, and atogepant. Gepants are taken orally, usually in the form of tablets. They are intended for use during a migraine attack and are not meant for preventive treatment. Gepants are typically self-administered by patients as needed, following the prescribed dosage instructions. These aspects contribute to the growth of the gepants segment.

CGRP Inhibitors Market by Distribution Channel

Based on the distribution channel, the global CGRP inhibitors market is segmented into hospital, retail, and online pharmacies.

The hospital pharmacies segment is a key player in the CGRP inhibitors market with the largest revenue share in 2022. Hospital pharmacies are responsible for dispensing CGRP inhibitors to patients. This includes receiving prescriptions from healthcare providers, verifying their accuracy and appropriateness, and preparing the medications for administration or distribution to patients. CGRP inhibitors, particularly monoclonal antibodies, often require specific storage conditions to maintain their stability and efficacy. Hospital pharmacies ensure proper storage and handling of these medications, including temperature control and protection from light. These overall factors contribute to the growth of the hospital pharmacies segment. 

The online pharmacies segment is expected to be the fastest-growing segment throughout the forecast period because of the convenience of having medicine delivered to your door. Online pharmacies refer to distributing and dispensing CGRP inhibitors through online platforms or e-pharmacies. Online pharmacies enable patients to place orders for CGRP inhibitors through their websites or mobile applications. Patients can browse the available medications, select the desired product, and complete the purchase online. This allows for easy and convenient access to CGRP inhibitors without needing to visit a physical pharmacy. Online pharmacies typically require patients to provide a valid prescription from a healthcare provider for CGRP inhibitors. They have mechanisms to verify prescriptions' authenticity and validity before processing orders. This ensures that patients receive the medication only when a qualified healthcare professional prescribes it. One of the key advantages of online pharmacies is the ability to deliver medications directly to the patient's doorstep. Once the order is placed and the prescription is verified, the CGRP inhibitors are packaged and shipped to the patient's designated address. Home delivery offers convenience and eliminates the need for patients to travel to a physical pharmacy. These overall factors contribute to the growth of the online pharmacy segment. 

CGRP Inhibitors Market by Region

Geographically, the global CGRP inhibitors market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

North America dominated the global CGRP inhibitors market with the largest revenue share in 2022, attributed to the high prevalence of migraines, strong pharmaceutical industry, and established healthcare infrastructure. Additionally, companies across the region are continuously involved in partnerships, mergers, and acquisitions, which are also expected to improve the CGRP inhibitors market outlook. Migraines are prevalent in North America, affecting a significant portion of the population. The burden of migraines in terms of healthcare costs and lost productivity has driven the demand for effective treatments, including CGRP inhibitors. Several CGRP inhibitors, including both monoclonal antibodies and gepants, have received regulatory approvals in North America. These approvals have facilitated the availability of these medications to patients in the region. North America is home to several prominent pharmaceutical companies actively involved in developing, producing, and marketing CGRP inhibitors. These companies are crucial in driving research and development efforts and bringing new CGRP inhibitors to the market. North America has been a hub for clinical trials and research related to CGRP inhibitors. Numerous clinical studies have been conducted in the region to evaluate the safety and efficacy of these medications, contributing to the growing body of evidence supporting their use.

CGRP Inhibitors Market Competitive Landscape

The prominent players operating in the global CGRP inhibitors market are:

CGRP Inhibitors Market Strategic Developments

  • In September 2021, AbbVie received approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant), an oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant). This marks a significant milestone as QULIPTA becomes the first and only medication of its kind approved for the preventive treatment of episodic migraine in adults. QULIPTA has been specifically developed to target the CGRP receptor and provide effective prevention of migraine episodes.
  • In March 2023, Pfizer Inc. received approval from the U.S. Food and Drug Administration (FDA) for ZAVZPRET (zavegepant), a nasal spray that acts as a calcitonin gene-related peptide (CGRP) receptor antagonist. This is a significant milestone as ZAVZPRET becomes the first and only nasal spray of its kind approved for the acute treatment of migraines in adults, whether with or without aura. The approval was based on the positive results from ZAVZPRET's pivotal Phase 3 study, where it demonstrated statistical superiority over placebo in achieving the co-primary endpoints of pain freedom and freedom from the most bothersome symptom at two hours after administration. Additionally, the study showed that ZAVZPRET provided pain relief as early as 15 minutes, as evaluated in a predetermined secondary endpoint when compared to a placebo.

Frequently Asked Questions About This Report

CGRP inhibitors, also known as calcitonin gene-related peptide inhibitors, are a class of medications used in the treatment of migraine headaches.

The revenue CAGR of the CGRP inhibitors market during the forecast period will be 5.4% from 2023 to 2031.

Some key companies operating in the global CGRP inhibitors market arePfizer Inc., Eli Lilly and Company, Novartis International AG, and Teva Pharmaceutical Industries Ltd.

The high cost of treatment, limited awareness and diagnosis, and competition from established therapies are factors restricting the global market growth to full potential.

The high prevalence of migraines and increasing awareness and diagnosis drive the market growth.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL CGRP INHIBITORS MARKET- ANALYSIS & FORECAST, BY DRUG CLASS
    1. Monoclonal Antibody            
      1. Eptinezumab
      2. Fremanezumab
      3. Galcanezumab
    2. Gepants         
      1. Ubrogepant
      2. Rimegepant 
      3. Atogepant
  6. GLOBAL CGRP INHIBITORS MARKET- ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
  7. GLOBAL CGRP INHIBITORS MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America CGRP Inhibitors Market
      1. North America CGRP Inhibitors Market, by Drug Class 
      2. North America CGRP Inhibitors Market, by Distribution Channel
      3. North America CGRP Inhibitors Market, by Country
        1. U.S.
          1. U.S. CGRP Inhibitors Market, by Drug Class 
          2. U.S. CGRP Inhibitors Market, by Distribution Channel
        2. Canada
          1. Canada CGRP Inhibitors Market, by Drug Class 
          2. Canada CGRP Inhibitors Market, by Distribution Channel
    2. Europe CGRP Inhibitors Market
      1. Europe CGRP Inhibitors Market, by Drug Class 
      2. Europe CGRP Inhibitors Market, by Distribution Channel 
      3. Europe CGRP Inhibitors Market, by Country/Region
        1. Germany
          1. Germany CGRP Inhibitors Market, by Drug Class 
          2. Germany CGRP Inhibitors Market, by Distribution Channel
        2. U.K.
          1. U.K. CGRP Inhibitors Market, by Drug Class 
          2. U.K. CGRP Inhibitors Market, by Distribution Channel
        3. France
          1. France CGRP Inhibitors Market, by Drug Class 
          2. France CGRP Inhibitors Market, by Distribution Channel
        4. Spain
          1. Spain CGRP Inhibitors Market, by Drug Class 
          2. Spain CGRP Inhibitors Market, by Distribution Channel
        5. Italy
          1. Italy CGRP Inhibitors Market, by Drug Class 
          2. Italy CGRP Inhibitors Market, by Distribution Channel
        6. Rest of Europe 
          1. Rest of Europe CGRP Inhibitors Market, by Drug Class 
          2. Rest of Europe CGRP Inhibitors Market, by Distribution Channel
    3. Asia Pacific CGRP Inhibitors Market
      1. Asia Pacific CGRP Inhibitors Market, by Drug Class 
      2. Asia Pacific CGRP Inhibitors Market, by Distribution Channel
      3. Asia Pacific CGRP Inhibitors Market, by Country/Region
        1. China
          1. China CGRP Inhibitors Market, by Drug Class 
          2. China CGRP Inhibitors Market, by Distribution Channel
        2. Japan
          1. Japan CGRP Inhibitors Market, by Drug Class 
          2. Japan CGRP Inhibitors Market, by Distribution Channel 
        3. India
          1. India CGRP Inhibitors Market, by Drug Class 
          2. India CGRP Inhibitors Market, by Distribution Channel
        4. South Korea
          1. South Korea CGRP Inhibitors Market, by Drug Class 
          2. South Korea CGRP Inhibitors Market, by Distribution Channel
        5. Australia
          1. Australia CGRP Inhibitors Market, by Drug Class 
          2. Australia CGRP Inhibitors Market, by Distribution Channel
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific CGRP Inhibitors Market, by Drug Class 
          2. Rest of Asia Pacific CGRP Inhibitors Market, by Distribution Channel
    4. Latin America CGRP Inhibitors Market
      1. Latin America CGRP Inhibitors Market, by Drug Class 
      2. Latin America CGRP Inhibitors Market, by Distribution Channel
      3. Latin America CGRP Inhibitors Market, by Country/ Region
        1. Brazil
          1. Brazil CGRP Inhibitors Market, by Drug Class 
          2. Brazil CGRP Inhibitors Market, by Distribution Channel
        2. Mexico
          1. Mexico CGRP Inhibitors Market, by Drug Class 
          2. Mexico CGRP Inhibitors Market, by Distribution Channel 
        3. Argentina
          1. Argentina CGRP Inhibitors Market, by Drug Class 
          2. Argentina CGRP Inhibitors Market, by Distribution Channel
        4. Rest of Latin America
          1. Rest of Latin America CGRP Inhibitors Market, by Drug Class 
          2. Rest of Latin America CGRP Inhibitors Market, by Distribution Channel 
    5. Middle East & Africa CGRP Inhibitors Market
      1. Middle East & Africa CGRP Inhibitors Market, by Drug Class 
      2. Middle East & Africa CGRP Inhibitors Market, by Distribution Channel
      3. Middle East & Africa CGRP Inhibitors Market, by Country/ Region
        1. GCC Countries
          1. GCC Countries CGRP Inhibitors Market, by Drug Class 
          2. GCC Countries CGRP Inhibitors Market, by Distribution Channel
        2. South Africa
          1. South Africa CGRP Inhibitors Market, by Drug Class 
          2. South Africa CGRP Inhibitors Market, by Distribution Channel 
        3. Rest of Middle East & Africa
          1. Rest of Middle East & Africa CGRP Inhibitors Market, by Drug Class 
          2. Rest of Middle East & Africa CGRP Inhibitors Market, by Distribution Channel
  8. COMPANY PROFILES         
    1. AbbVie Inc.
      1. Business Snapshot 
      2. Products Offered
      3. Financial Details
      4. Strategic Development
    2. Pfizer Inc. 
    3. Eli Lilly and Company
    4. Novartis International AG
    5. Teva Pharmaceutical Industries Ltd.

*Insights on financial performance are subject to the availability of information in the public domain

List of Tables

 

  1. Global CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million)
  2. Global CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  3. Global CGRP Inhibitors Market, by Region, 2021-2031 (US$ Million) 
  4. North America CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  5. North America CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  6. North America CGRP Inhibitors Market, by Country, 2021-2031 (US$ Million) 
  7. U.S. CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  8. U.S. CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  9. Canada CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  10. Canada CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  11. Europe CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  12. Europe CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  13. Europe CGRP Inhibitors Market, by Country/ Region, 2021-2031 (US$ Million) 
  14. Germany CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  15. Germany CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  16. U.K. CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  17. U.K. CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  18. France CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  19. France CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  20. Italy CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  21. Italy CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  22. Spain CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  23. Spain CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  24. Rest of Europe CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  25. Rest of Europe CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  26. Asia Pacific CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  27. Asia Pacific CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  28. Asia Pacific CGRP Inhibitors Market, by Country/ Region, 2021-2031 (US$ Million) 
  29. China CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  30. China CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  31. Japan CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  32. Japan CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  33. India CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  34. India CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  35. South Korea CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  36. South Korea CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  37. Australia CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  38. Australia CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  39. Rest of Asia Pacific CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  40. Rest of Asia Pacific CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  41. Latin America CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  42. Latin America CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  43. Latin America CGRP Inhibitors Market, by Country/ Region, 2021–2031 (US$ Million)
  44. Brazil CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  45. Brazil CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  46. Mexico CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  47. Mexico CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  48. Argentina CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  49. Argentina CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  50. Rest of Latin America CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  51. Rest of Latin America CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  52. Middle East and Africa CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  53. Middle East and Africa CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  54. Middle East and Africa CGRP Inhibitors Market, by Country/ Region, 2021–2031 (US$ Million)
  55. GCC Countries CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  56. GCC Countries CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  57. South Africa CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  58. South Africa CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  59. Rest of Middle East & Africa CGRP Inhibitors Market, by Drug Class, 2021-2031 (US$ Million) 
  60. Rest of Middle East & Africa CGRP Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 

List of Figures

 

  1. CGRP Inhibitors Market Ecosystem  
  2. Snapshot of Global CGRP Inhibitors Market, 2021 & 2031 
  3. Snapshot of Global CGRP Inhibitors Market, by Region, 2021 & 2031 
  4. Global CGRP Inhibitors Market: COVID-19 Pandemic Impact Assessment 
  5. Global CGRP Inhibitors Market: Key Players & Competitive Positioning (2022) 
  6. CGRP Inhibitors: Market Dynamics 
  7. Global CGRP Inhibitors Treatment Market for Monoclonal Antibody, 2021-2031 (US$ Million)
  8. Global CGRP Inhibitors Treatment Market for Eptinezumab, 2021-2031 (US$ Million)
  9. Global CGRP Inhibitors Treatment Market for Fremanezumab, 2021-2031 (US$ Million)
  10. Global CGRP Inhibitors Treatment Market for Galcanezumab, 2021-2031 (US$ Million)
  11. Global CGRP Inhibitors Treatment Market for Gepants, 2021-2031 (US$ Million)
  12. Global CGRP Inhibitors Treatment Market for Ubrogepant, 2021-2031 (US$ Million)
  13. Global CGRP Inhibitors Treatment Market for Rimegepant, 2021-2031 (US$ Million)
  14. Global CGRP Inhibitors Treatment Market for Atogepant, 2021-2031 (US$ Million)
  15. Global CGRP Inhibitors Treatment Market for Hospital Pharmacies, 2021-2031 (US$ Million)
  16. Global CGRP Inhibitors Treatment Market for Retail Pharmacies, 2021-2031 (US$ Million)
  17. Global CGRP Inhibitors Treatment Market for Online Pharmacies, 2021-2031 (US$ Million)
  18. North America CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  19. U.S. CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  20. Canada CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  21. Europe CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  22. Germany CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  23. U.K. CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  24. France CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  25. Italy CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  26. Spain CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  27. Rest of Europe CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  28. Asia Pacific CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  29. China CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  30. Japan CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  31. India CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  32. South Korea CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  33. Australia CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  34. Rest of Asia Pacific CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  35. Latin America CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  36. Brazil CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  37. Mexico CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  38. Argentina CGRP Inhibitors Market, 2021-2031 (US$ Million)
  39. Rest of Latin America CGRP Inhibitors Market, 2021-2031 (US$ Million)
  40. Middle East & Africa CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  41. GCC Countries CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  42. South Africa CGRP Inhibitors Market, 2021-2031 (US$ Million) 
  43. Rest of Middle East & Africa CGRP Inhibitors Market, 2021-2031 (US$ Million)
  44. AbbVie Inc. Revenue from 2019 Onwards (US$ Million)
  45. Pfizer Inc. Revenue from 2019 Onwards (US$ Million)
  46. Eli Lilly and Company Revenue from 2019 Onwards (US$ Million)
  47. Novartis International AG Revenue from 2019 Onwards (US$ Million)
  48. Teva Pharmaceutical Industries Ltd. Revenue from 2019 Onwards (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the CGRP Inhibitors Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the CGRP Inhibitors Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports